500556-94-5

Basic information

• Product Name: 7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,2R,4R)-
• CAS NO: 500556-94-5
• Molecular Formula: C19H26N2O4
• Molecular Weight: 346.426
• Mol File: 500556-94-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,2R,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,2R,4R)-(500556-94-5)
• EPA Substance Registry System: 7-Azabicyclo[2.2.1]heptane-7-carboxylic acid, 2-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (1S,2R,4R)-(500556-94-5)

Safety Data

• Hazardous Substances Data: 500556-94-5(Hazardous Substances Data)

Upstream product

• 1250884-79-7 (+/-) exo-tert-butyl-2-{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 1221818-81-0 (1S,2R,4R)-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 1250884-79-7 tert-butyl exo-2-{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate 

Downstream Products

• 500556-90-1 exo-tert-butyl (1S,2R,4R)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 500556-90-1 exo-tert-butyl(1S, 2R, 4R)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 500556-90-1 (+)-(1S,2R,4R)-tert-butyl 2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate 

Relevant articles and documents

SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

COMPOUNDS HAVING BOTH α7 NICOTINIC AGONIST ACTIVITY AND 5HT3 ANTAGONIST ACTIVITY FOR TREATMENT OF CNS DISEASES

The invention discloses compounds that are selective α7 nAChR agonists and 5-HT3 antagonists. The compounds are useful for treating many CNS diseases.

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.